Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: Serious immune related adverse events across a spectrum of cancer subtypes

Pituitary

Volumn 13, Issue 1, 2010, Pages 29-38

  Dillard, Troy ^a   Yedinak, Chris G ^a   Alumkal, Joshi ^b   Fleseriu, Maria ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Autoimmune hypophysitis; Cytotoxic T lymphocyte antigen 4; Drug induced hypophysitis; Hypopituitarism; Immune related adverse events (IRAEs); Lymphocytic hypophysitis; Prostate cancer

Indexed keywords

BICALUTAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DEXAMETHASONE; GLUCOCORTICOID; HYDROCORTISONE; IPILIMUMAB; LEUPRORELIN; LEVOTHYROXINE; PREDNISONE; TICILIMUMAB;

ADRENAL INSUFFICIENCY; ADVERSE OUTCOME; ALOPECIA AREATA; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; ARTICLE; ASEPTIC MENINGITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; AUTOIMMUNITY; BEDTIME DOSAGE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLITIS; DERMATITIS; DIABETES INSIPIDUS; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG WITHDRAWAL; ENTERITIS; EPISCLERITIS; ERYTHROCYTE APLASIA; FOLLOW UP; GASTRITIS; HEPATITIS; HISTOPATHOLOGY; HUMAN; HYPOPHYSIS THYROID SYSTEM; HYPOPHYSITIS; HYPOPITUITARISM; INTERSTITIAL NEPHRITIS; IRITIS; KIDNEY CARCINOMA; LONG TERM CARE; LUNG ALVEOLITIS; LUNG CANCER; LYMPHOMA; MELANOMA; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; OVARY CANCER; PANCREAS CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; SOLID TUMOR; THYROIDITIS; UROGENITAL TRACT TUMOR; UVEITIS; VITILIGO;

AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; AUTOIMMUNE DISEASES; CARCINOMA, RENAL CELL; HUMANS; MALE; MELANOMA; MIDDLE AGED; PITUITARY DISEASES; PROSTATIC NEOPLASMS;

EID: 77949274549     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-009-0193-z     Document Type: Article

References (41)

1. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541-547
2. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985-988
3. van Elsas A, Hurwitz AA, Allison JP (1999) Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190:355-366
4. Hurwitz AA, Yu TF, Leach DR, Allison JP (1998) CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci USA 95:10067-10071
5. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP (2000) Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60:2444-2448
6. Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734-1736
7. R Houot R Levy 2009 T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy Blood 113 3546 3552 10.1182/blood-2008-07-170274 1:CAS:528:DC%2BD1MXkslCku7c%3D 18941113
8. M Jinushi FS Hodi G Dranoff 2006 Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity Proc Natl Acad Sci 103 9190 9195 10.1073/pnas.0603503103 1:CAS:528:DC%2BD28XmsVWjtr4%3D 16754847 (Pubitemid 43902554)
9. Contardi E, Palmisano GL, Tazzari PL, Martelli AM, Fala F, Fabbi M, Kato T, Lucarelli E, Donati D, Polito L, Bolognesi A, Ricci F, Salvi S, Gargaglione V, Mantero S, Alberghini M, Ferrara GB, Pistillo MP (2005) CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer 117:538-550
10. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23:6043-6053
11. KY Chung I Gore L Fong A Venook P Dorazio D Healey D Pavlov LB Saltz 2007 A phase II study of the anti-CTLA4 monoclonal antibody (mAb), CP-675, 206,in patients with refractory metastatic adenocarcinoma of the colon or rectum J Clin Oncol 25 3035 (Meeting Abstracts)
12. Davis TA, Tchekmedyian S, Korman A, Keler T, Deo Y, Small EJ (2002) MDX-010 (human anti-CTLA4): a phase 1 trial in hormone refractory prostate carcinoma (HRPC). Proc Am Soc Clin Oncol 21:74
13. Fischkoff SA, Hersh E, Weber J, Powderly J, Khan K, Pavlick A, Samlowski W, O'Day S, Nichol G, Yellin M (2005) Durable responses and progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma. J Clin Oncol 23:7525 (Meeting Abstracts)
14. Fong L, Kavanagh B, Rini BI, Shaw V, Weinberg V, Small EJ (2006) A phase I trial of combination immunotherapy with CTLA-4 blockade and GM-CSF in hormone-refractory prostate cancer. J Clin Oncol 24:2508 (Meeting Abstracts)
15. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100:4712-4717
16. Morton DL, Mozzillo N, Thompson JF, Kelley MC, Faries M, Wagner J, Schneebaum S, Schuchter L, Gammon G, Elashoff R, Group MCT (2007) An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol 25:8508 (Meeting Abstracts)
17. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372-8377
18. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA, Gomez-Navarro J (2005) Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675, 206. J Clin Oncol 23:8968-8977
19. Thompson RH, Allison JP, Kwon ED (2006) Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urol 24:442-447
20. Weber JS, Targan S, Scotland R, Snively J, Garcia M, Yellin M, Fischkoff S, Nicho l (2006) Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multi-peptide vaccine for resected stages IIIC and IV melanoma. J Clin Oncol 24: 2510 (Meeting Abstracts)
21. Yang JC, Beck KE, Blansfield JA, Tran KQ, Lowy I, Rosenberg SA (2005) Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010). J Clin Oncol 23:2501 (Meeting Abstracts)
22. Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, Royal RE, Topalian SL, Haworth LR, Levy C, Rosenberg SA, Sherry RM (2005) Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 28:593-598
23. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13:6681-6688
24. Gordon IO, Wade T, Chin K, Dickstein J, Gajewski TF (2009) Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma Cancer. Immunol Immunother 58:1351-1353
25. Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, Kleiner D, Mavroukakis SA, Yellin M, Rosenberg SA (2005) Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 12:1005-1016
26. Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Hughes M, Yellin MJ, Haworth LR, Levy C, Allen T, Mavroukakis SA, Attia P, Rosenberg SA (2006) Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 29:455-463
27. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP (2007) A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 13:1810-1815
28. JS Weber S O'Day W Urba J Powderly G Nichol M Yellin J Snively E Hersh 2008 Phase I/II study of ipilimumab for patients with metastatic melanoma J Clin Oncol 26 5950 5956 10.1200/JCO.2008.16.1927 1:CAS:528:DC%2BD1MXhs1Ggurc%3D 19018089
29. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA (2007) Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30:825-830
30. Simmons AD, Moskalenko M, Creson J, Fang J, Yi S, VanRoey MJ, Allison JP, Jooss K (2008) Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. Cancer Immunol Immunother 57:1263-1270
31. Weber J (2007) Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12:864-872
32. Caturegli P, Lupi I, Landek-Salgado M, Kimura H, Rose NR (2008) Pituitary autoimmunity: 30 years later Autoimmunity. Reviews 7:631-637
33. T Abe 2008 Lymphocytic infundibulo-neurohypophysitis and infundibulo-panhypophysitis regarded as lymphocytic hypophysitis variant Brain Tumor Pathol 25 59 66 10.1007/s10014-008-0234-8 18987830
34. T Abe K Matsumoto N Sanno Y Osamura 1995 Lymphocytic hypophysitis: case report Neurosurgery 36 1016 1019 10.1097/00006123-199505000-00020 1:STN:280:DyaK2Mzht1Wkug%3D%3D 7791966
35. Beressi N, Beressi JP, Cohen R, Modigliani E (1999) Lymphocytic hypophysitis. A review of 145 cases. Ann Med Interne (Paris) 150:327-341
36. ER Laws ML Vance JA Jane Jr 2006 Hypophysitis Pituitary 9 331 333 10.1007/s11102-006-0415-6 17080263 (Pubitemid 44823902)
37. Leung GK, Lopes MB, Thorner MO, Vance ML, Laws ER, Jr (2004) Primary hypophysitis: a single-center experience in 16 cases. J Neurosurg 101:262-271
38. JA Rivera 2006 Lymphocytic hypophysitis: disease spectrum and approach to diagnosis and therapy Pituitary 9 35 45 10.1007/s11102-006-6598-z 16703407 (Pubitemid 43733081)
39. N Tubridy D Saunders M Thom SL Asa M Powell GT Plant R Howard 2001 Infundibulohypophysitis in a man presenting with diabetes insipidus and cavernous sinus involvement J Neurol Neurosurg Psychiatry 71 798 801 10.1136/jnnp.71.6.798 1:STN:280:DC%2BD3MnnslWgtQ%3D%3D 11723207 (Pubitemid 33121926)
40. EA McIntyre P Perros 2007 Fatal inflammatory hypophysitis Pituitary 10 107 111 10.1007/s11102-007-0016-z 17318440 (Pubitemid 46562815)
41. L Ward J Paquette E Seidman C Huot F Alvarez P Crock E Delvin O Kampe C Deal 1999 Severe autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy in an adolescent girl with a novel AIRE mutation: response to immunosuppressive therapy J Clin Endocrinol Metab 84 844 852 10.1210/jc.84.3.844 1:CAS:528:DyaK1MXhvFegtLo%3D 10084559